Semaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis: a case report Dr Kartikeya Kohli21 April 2025 9:00 AM ISTSemaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis suggests a case report published in the BMC...
Conduct CT in India: CDSCO Panel tells Novo Nordisk India For new formulation of Semaglutide tablets Dr. Divya Colin17 April 2025 5:30 PM ISTNew Delhi: In line with the proposal for approval of Semaglutide tablets 1.5 mg, 4 mg, 9 mg of new formulation based on the bioequivalence (BE)...
Lean muscle mass loss minimized during weight loss therapy using newer incretin obesity drugs, suggests study Dr. Kamal Kant Kohli11 April 2025 9:15 AM ISTNew research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or...
Semaglutide Boosts Walking Capacity in PAD and Type 2 Diabetes, STRIDE Trial Finds Medha Baranwal3 April 2025 9:15 AM ISTUSA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with peripheral artery disease (PAD)...
Study Links Semaglutide to Increased NAION Risk in Diabetes Patients Medha Baranwal29 March 2025 7:45 AM ISTTaiwan: A recent cohort study published in JAMA Ophthalmology suggests that patients with diabetes who use semaglutide may face an increased risk of...
Anti-Obesity Drugs Tirzepatide and Semaglutide Offer Health Benefits but Cost found prohibitive: New Research Shows Medha Baranwal20 March 2025 9:30 AM ISTUSA: A recent economic evaluation has highlighted the significant long-term health benefits of tirzepatide and semaglutide in managing obesity among...
No Long-Term Safety Data: CDSCO Panel Denies Novo Nordisk's proposal to amend warning statement of Semaglutide Dr. Divya Colin16 March 2025 5:15 PM ISTNew Delhi: Citing that there is no real world long-term safety data for Novo Nordisk's antidiabetic drug Semaglutide tablets (3 mg, 7 mg, 14 mg), the...
Anti-obesity drugs benefit kidney transplant recipients with type 2 diabetes: Study Dr. Kamal Kant Kohli15 March 2025 9:00 AM ISTKidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and...
Taking semaglutide before bariatric surgery does not improve weight loss or safety, reveals research Dr. Kamal Kant Kohli14 March 2025 8:15 PM ISTMass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery,...
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk Ruchika Sharma14 March 2025 2:00 PM ISTDenmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo...
Hetero Labs Gets CDSCO Panel Nod To study Semaglutide Injection for Type 2 Diabetes Mellitus Dr. Divya Colin10 March 2025 6:00 PM ISTNew Delhi: Hetero Labs has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization...
Alkem Laboratories Gets CDSCO Panel Nod To study Semaglutide tablet for Type 2 Diabetes Mellitus Dr. Divya Colin9 March 2025 6:00 PM ISTNew Delhi: Alkem Laboratories has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
